Key facts
- It has raised $1.2M; the latest was Seed Round ($2.5M) in Oct 2025.
- Notable investors include Venture Kick, European Commission, Ecole Polytechnique Federale de Lausanne, Alexandra Gaudiani, Bundesministerium für Bildung und Forschung — 13 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Sensars
- ·The full record, as it builds
Funding rounds
No funding rounds for Sensars are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Sensars
Developer of an implantable neurostimulation device designed to restore foot sensation in people with diabetic neuropathy. The company offers an implantable neurostimulator that restores sensory feedback, enabling patients with diabetic neuropathy to reduce the risk of falls, ulcers, amputations, and chronic pain.
- Sector
- Healthcare
- HQ
- West Grove, PA, United States
- Founded
- 2014
- Employees
- 2
- Website
- sensars.com/
- Ownership
- Privately Held (backing)
Sensars doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Sensars shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Sensars in its N-PORT filings yet. We sweep new filings monthly.